Icotinib
- Generic Name
- Icotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N3O4
- CAS Number
- 610798-31-7
- Unique Ingredient Identifier
- 9G6U5L461Q
- Background
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...
- Indication
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT02125240
- Locations
- 🇨🇳
304 Hospital of PLA, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT02103257
- Locations
- 🇨🇳
Urumqi General Hospital of Lanzhou Military Region General Hospital, Urumqi, Xinjiang, China
🇨🇳Jiangmen central hospital, Jiangmen, Guangdong, China
🇨🇳Medical Oncology,Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT02066870
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02062515
- Locations
- 🇨🇳
Sun Yat-sen Cancer Center, Guangzhou, Guangdong, China
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02044328
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 250
- Registration Number
- NCT02031601
- Locations
- 🇨🇳
Yu Li, Jinan, Shandong, China
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02024633
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang Univercity School of Medcine, Hangzhou, China
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT02009605
- Locations
- 🇨🇳
79 Qingchun Road, Hangzhou, Zhejiang, China
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Anhui Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT01963195
- Locations
- 🇨🇳
Dept. of Oncology,The First Affiliated Hospital of Anhui Medical Univesrsity, Hefei, Anhui, China
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT01855854
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.